I agree that this site is using cookies. You can find further informations here.
X
Špicka, Ivan
222  results:
Search for persons X
?
1

Nivolumab, Pomalidomide, and Elotuzumab Combination Regimen..:

Oriol, Albert ; Hájek, Roman ; Spicka, Ivan...
Clinical Lymphoma Myeloma and Leukemia.  , 2024
Link: https://doi.org/10.1016/..
 
?
2

Isatuximab in combination with carfilzomib and dexamethason..:

Facon, Thierry ; Moreau, Philippe ; Špicka, Ivan...
Hematological Oncology.  42 (2024)  2 - p. , 2024
Link: https://doi.org/10.1002/..
 
?
3

Isatuximab-pomalidomide-dexamethasone versus pomalidomide-d..:

Richardson, Paul G. ; Perrot, Aurore ; Miguel, Jesus San...
Haematologica.  , 2024
Link: https://doi.org/10.3324/..
 
?
4

Health-related quality of life in relapsed/refractory multi..:

Schjesvold, Fredrik H. ; Ludwig, Heinz ; Delimpasi, Sossana...
Haematologica.  , 2024
Link: https://doi.org/10.3324/..
 
?
5

Efficacy and safety of melflufen plus daratumumab and dexam..:

Pour, Luděk ; Szarejko, Monika ; Bila, Jelena...
Haematologica.  109 (2023)  3 - p. 895-905 , 2023
Link: https://doi.org/10.3324/..
 
?
6

P-110 Ixazomib maintenance in transplant-ineligible patient..:

Dimopoulos, Meletios ; Chng, Wee Joo ; Iida, Shinsuke...
Clinical Lymphoma Myeloma and Leukemia.  23 (2023)  - p. S95 , 2023
Link: https://doi.org/10.1016/..
 
?
7

Patient Characteristics, Treatment Patterns, and Outcomes i..:

Maisnar, Vladimir ; Pour, Ludek ; Spicka, Ivan...
Clinical Lymphoma Myeloma and Leukemia.  23 (2023)  2 - p. 145-153 , 2023
Link: https://doi.org/10.1016/..
 
?
8

Clinical characteristics and outcomes in risk-stratified pa..:

Sandecka, Viera ; Popkova, Tereza ; Stork, Martin...
Blood Cancer Journal.  13 (2023)  1 - p. , 2023
Link: https://doi.org/10.1038/..
 
?
9

POSTER: MM-182 Allocation and Validation of the Second Revi..:

Perrot, Aurore ; Richardson, Paul ; Mikhael, Joseph...
Clinical Lymphoma Myeloma and Leukemia.  23 (2023)  - p. S216 , 2023
Link: https://doi.org/10.1016/..
 
?
10

P916: LONG-TERM OUTCOMES WITH ISATUXIMAB-CARFILZOMIB-DEXAME..:

Facon, Thierry ; Moreau, Philippe ; Špicka, Ivan...
HemaSphere.  7 (2023)  S3 - p. e7523284 , 2023
Link: https://doi.org/10.1097/..
 
?
11

Correction: Isatuximab, carfilzomib, and dexamethasone in p..:

Martin, Thomas ; Dimopoulos, Meletios-Athanasios ; Mikhael, Joseph...
Blood Cancer Journal.  13 (2023)  1 - p. , 2023
Link: https://doi.org/10.1038/..
 
?
12

P944: REAL-WORLD PATIENT CHARACTERISTICS AND SURVIVAL OUTCO..:

Spicka, Ivan ; Lapidot, Ido ; Merz, Maximilian...
HemaSphere.  7 (2023)  S3 - p. e258126d , 2023
Link: https://doi.org/10.1097/..
 
?
13

OA-48 Isatuximab plus carfilzomib and dexamethasone versus ..:

Yong, Kwee ; Martin, Thomas ; Dimopoulos, Meletios...
Clinical Lymphoma Myeloma and Leukemia.  23 (2023)  - p. S30-S31 , 2023
Link: https://doi.org/10.1016/..
 
?
14

MRD dynamics during maintenance for improved prognosticatio..:

Paiva, Bruno ; Manrique, Irene ; Dimopoulos, Meletios A....
Blood.  141 (2023)  6 - p. 579-591 , 2023
Link: https://doi.org/10.1182/..
 
?
15

Association of Selinexor Dose Reductions With Clinical Outc..:

Jagannath, Sundar ; Delimpasi, Sosana ; Grosicki, Sebastian...
Clinical Lymphoma Myeloma and Leukemia.  23 (2023)  12 - p. 917-923.e3 , 2023
Link: https://doi.org/10.1016/..
 
1-15